OR WAIT 15 SECS
The assay will provide information on biosimilar comparability.
Sartorius Stedim subsidiary BioOutsource announced on July 7, 2016 that it is launching a new biosimilarity comparability tool to measure IgG glycosylation. The tool incorporates a collection of orthogonal methods, including analysis by CD16a (FcγRIIIa), surface plasmon resonance spectroscopy for ligand binding, and antibody-dependent cell-mediated cytotoxicity (ADCC) functional assays.
The tool will generate information on the molecular structure of a drug as well as its key mechanism of action, allowing scientists to accurately characterize their investigational biosimilar molecule and identify glycosylation patterns.
“The structural classification and monosaccharide composition of carbohydrates attached to the constant region of therapeutic biosimilar antibodies is key to their binding,” said Daniel Galbraith, CSO at Sartorius Stedim BioOutsource, in a press release. “An accurate understanding of these glycans ensures effective selection of biosimilars that have the optimum ADCC activity to destroy tumor cells.”
Source: Sartorius Stedim BioOutsource